Disclosed are methods and compositions related to the use cannabinoids as adjuvants for the accelerated induction and production of an antibody based immune response.

Disclosed are compositions comprising a Gram negative needle tip protein and a translocator protein and methods of their use.

Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.

Disclosed herein are compositions comprising immunomodulatory and oncolytic eubacterial minicells, and the use of the composition in immunomodulatory therapies for cancer. In some embodiments, the minicells are used in combination of immune checkpoint inhibitors in treating cancer.

The present invention provides isolated polypeptides isolatable from a Yersinia spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.

Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.

Disclosed is a gastro-resistant vector for the oral administration of at least one pharmaceutical and/or antigenic active substance including an aqueous phase (W) and an oily phase (O) in the form of a water-in-oil (W/O)-type emulsion wherein the aqueous phase includes at least one active principle and between 2 and 40 wt. % of a hydrophilic polymer that is insoluble in an aqueous phase of pH<6.5.

Embodiments of the disclosure provide for unique lipooligosaccharide/lipid A-based mimetics for use as adjuvants. Methods of generating lipooligosaccharide/lipid A-based mimetics are provided that utilize recombinantly engineered bacteria to produce the mimetics, including, for example, addition of one or more particular enzymes such as acyltransferases, deacylases, phosphatases, or glycosyltransferases.

Provided herein are imidazopyrimidine compounds, such as compounds of Formula (I), for use in enhancing human immune response and/or as adjuvants in vaccines. ##STR00001##

A method of immunizing a susceptible host against a pathogen comprising administering to the host a vaccine that comprises an attenuated recombinant live vaccine strain lacking a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses an antigen of at least one pathogen from Table 1; or administering to the host a vaccine that comprises an attenuated Listeria monocytogenes expressing the antigen of the pathogen from Table 1; or administering to the host a prime vaccine and a heterologous booster vaccine where the prime vaccine comprises an attenuated recombinant live vaccine strain lacking a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses an antigen of at least one pathogen from Table 1 and the heterologous booster vaccine comprises an attenuated Listeria monocytogenes expressing the antigen of the pathogen from Table 1.